Telomerase holoenzyme complex and methods of use thereof
A biotin-tagged recombinant telomerase holoenzyme complex, delivered via cell-penetrating peptides, addresses inefficiencies and safety concerns of existing methods by transiently elongating telomeres and extending cell lifespan without causing transformation, suitable for therapeutic applications.
Patent Information
- Application Number
- JP2024126506
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-09-06
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods for extending telomere length and proliferative capacity of cells, such as antigen-specific T cells, face challenges including inefficiency, safety concerns, and potential for cancerous transformation due to viral vector integration and constant telomerase expression, which limits their use in immunotherapy and other therapeutic applications.
The development of a biotin-tagged recombinant telomerase holoenzyme complex, purified using a three-step process, is delivered into cells via cell-penetrating peptides, allowing transient telomerase activity to elongate telomeres without causing immortalization or transformation, thereby extending the replicative lifespan of cells.
The method effectively extends telomere length and replicative lifespan of cells, maintaining telomerase activity in both cytoplasmic and nuclear compartments, and does not lead to cellular transformation, making it suitable for therapeutic applications like adoptive immunotherapy.
Smart Images

Figure 2024156858000010 
Figure 2024156858000011 
Figure 2024156858000012
Abstract
Description
[Technical field]
[0001] Priority claim This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 727,743, filed September 6, 2018, the entire contents of which are incorporated herein by reference.
[0002] 1. Field The present disclosure relates to the fields of cell biology, molecular biology, protein biology, and medicine. More specifically, the present disclosure describes the production and delivery of a telomerase holoenzyme complex to cells to slow or correct telomere shortening. [Background technology]
[0003] 2. Description of Related Art Telomeres are tandem repeats that cap the ends of linear chromosomes, protecting them from degradation and preventing chromosome fusion [1]. In normal human proliferating cells, telomeres progressively shorten with each cell division [2], eventually triggering DNA damage response, replicative senescence, or apoptosis [3]. As a consequence of proliferation, telomere length shortens with age [4] and is considered a biomarker of biological (but not chronological) age [5], which also correlates with various age-related pathologies, including cancer [3], dementia [6, 7], and cardiovascular disease [5]. Recent studies in mice have shown that preventing telomere shortening, a hallmark of aging, increases both healthspan and lifespan [8, 9].
[0004] Telomerase, the reverse transcriptase responsible for the de novo addition of telomeric TTAGGG repeats at the ends of telomeres, is a ribonucleoprotein enzyme complex composed of two major components, the catalytic protein subunit (TERT) and the template RNA (TR or TERC). In humans, TERT is normally expressed exclusively in cells capable of long-term proliferation (e.g., proliferative non-quiescent stem cells) but not in normal differentiated somatic cells, except in activated lymphocytes [10, 11].
[0005] T lymphocytes (T cells) are the central cell type in the immune system, circulating mostly in a non-proliferative resting state but rapidly dividing when activated with antigen or non-specific stimuli
[11] . In vitro, T cells can be activated and proliferate in response to specific antigen or non-specific (mitogenic anti-CD3 and anti-CD28 antibodies) stimuli
[11] . Although telomerase activity is transiently upregulated in activated human T cells, this telomerase is not sufficient to counteract telomere loss during rapid cell proliferation, ultimately resulting in replicative senescence both in vitro and in vivo [11, 12]. Thus, telomere length and the ability to reactivate telomerase activity are key factors determining the lifespan of T cells and the antitumor activity of tumor-infiltrating lymphocytes (TILs), which mediate tumor regression in patients with healthy immune responses [13, 14]. Indeed, TILs with longer telomeres can persist longer in vivo and mediate more robust antitumor effects [ 15 ].
[0006] Due to their antitumor capabilities, human antigen-specific T cells are increasingly being used as a major tool in adoptive immunotherapy to treat various forms of cancer and infectious diseases such as AIDS [16, 17]. It is now possible to modify a patient's autologous T cells with cancer antigen-specific T cell receptor genes and adoptively transfer the modified in vitro expanded T cells into the host. However, with prolonged culture and expansion in vitro, the modified T cells have limited replicative capacity in vivo and eventually enter a senescent state (T cell exhaustion) due to the progressive loss of telomeric DNA. Senescent cells have rather limited potential for use in immunotherapy, so a technology that provides a means to efficiently protect T cells from telomere loss during rapid expansion in vitro would be highly advantageous for successful clinical application of antigen-specific T cells and many other cell types. Summary of the Invention
[0007] overview As described below, we have successfully engineered a biotin-tagged recombinant hTERT and overexpressed it together with hTR (the functional RNA component of telomerase) in the human cell line H1299. We have also developed a three-step purification procedure strategy to purify recombinant telomerase from cell lysates. This multi-step purification procedure allowed us to obtain highly enriched, catalytically active enzyme. Importantly, we have utilized our own developed biotin tag, which allowed us to pull down the entire reconstituted telomerase holoenzyme complex, including not only telomerase (hTERT+hTR) but also other essential telomerase-associated proteins, such as dyskerin (DKC1), ribonucleoproteins NOP10 and NHP2. We delivered purified telomerase holoenzyme into normal young and old human cells (e.g., antigen-stimulated peripheral blood mononuclear cells and lung fibroblasts) by using a combination of a cell-penetrating peptide and an active uptake mechanism induced by NaCl-mediated hyperosmolarity. The delivered telomerase retained robust activity in both the cytoplasmic and nuclear compartments. We also demonstrated that three consecutive deliveries of telomerase in vitro (every 3 days) were sufficient to significantly extend both telomere length and the replicative lifespan of cells. Importantly, this treatment did not immortalize or transform cells that eventually underwent senescence, and the delivered telomerase holoenzyme remained active for a limited time frame (up to 24-36 hours). We can utilize this human recombinant telomerase holoenzyme to transiently elongate telomeres and thus extend the replicative lifespan of old human cells.
[0008] Thus, in accordance with the present disclosure, there is provided a method of increasing telomere length and / or increasing the proliferative potential of a cell, comprising: (i) providing a cell population; (ii) contacting at least a first portion of the cell population with purified recombinant telomerase holoenzyme; and (iii) measuring expression of one or more target genes regulated by telomere length in cells from the first portion. The method may further comprise (iv) introducing a second cell from the first portion into a subject if one or more of the target genes exhibit an expression profile indicative of telomerase activity, as compared to untreated cells, such as untreated cells from a second portion of the cell population.
[0009] The method may further comprise, prior to step (ii), measuring expression of one or more target genes regulated by telomere length in a third cell of the cell population. The one or more target genes may be ISG15, TEAD4, PD-1, and / or BAX. The cell population may be PBMCs. The cell population may be CD3 + / CD28 + The cell population may be a T cell, such as a T cell. The method may further comprise removing the cell population from the subject prior to step (i). The subject may be a human subject or a humanized mouse, such as a NOD SCID gamma mouse, with umbilical cord blood stem cells. The telomerase holoenzyme may be conjugated to a cell-penetrating peptide.
[0010] In another embodiment, a method of increasing the proliferative potential of a cell is provided, comprising the steps of: (i) providing a cell population; (ii) contacting the first portion of the cell population with recombinant telomerase holoenzyme; (iii) measuring the total number of cell divisions undergone by a first cell from the first portion before senescence or apoptosis is induced; (iv) measuring the total number of cell divisions undergone by cells from a second portion of the cell population, but a portion that is not telomerase treated, before senescence or apoptosis is induced; and (v) determining whether a second cell from the first portion does not exhibit a hallmark of cancer. The method may further comprise introducing a third cell from the first portion into a subject if the total number of cell divisions measured in step (iii) is greater than the total number of cell divisions measured in step (iv) and if the second cell from the first portion does not exhibit a hallmark of cancer.
[0011] The method may further comprise (a) as part of step (iii) or (b) in the case of a fourth cell from the cell population prior to step (ii), measuring telomere length and / or expression of one or more target genes regulated by telomere length. The one or more target genes may be ISG15, TEAD4, PD-1, and / or BAX. The cell population may be PBMCs. The cell population may be CD3 + / CD28 + The cell population may be a T cell, such as a T cell. The method may further comprise removing the cell population from the subject prior to step (i). The subject may be a human subject or a humanized mouse, such as a NOD SCID gamma mouse, with umbilical cord blood stem cells. The telomerase holoenzyme may be conjugated to a cell-penetrating peptide.
[0012] It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein.
[0013] The use of the words "a" or "an" when used in conjunction with the term "comprising" in the claims and / or specification can mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one." The word "about" means plus or minus 5% of the specified number.
[0014] [The present invention 1001] 1. A method for increasing telomere length and / or increasing the proliferative potential of a cell, comprising: (i) providing a population of cells; (ii) contacting at least a first portion of the cell population with purified recombinant telomerase holoenzyme; and (iii) measuring expression of one or more target genes that are regulated by telomere length in cells from said first portion. The method comprising: [The present invention 1002] (iv) introducing a second cell from the first portion into the subject if one or more of the target genes exhibit an expression profile indicative of telomerase activity compared to an untreated cell, such as an untreated cell, from a second portion of the cell population. The method of the present invention 1001 further comprises: [The present invention 1003] prior to step (ii), measuring expression of one or more target genes that are regulated by telomere length in a third cell of said cell population. The method of the present invention 1001 or 1002 further comprising: [The present invention 1004] The method of any of claims 1001 to 1003, wherein said one or more target genes are ISG15, TEAD4, PD-1, and / or BAX. [The present invention 1005] The method according to any one of claims 1001 to 1004, wherein the cell population is PBMC. [The present invention 1006] The cell population is CD3 + / CD28 + The method according to any one of claims 1001 to 1004, wherein the subject is a T cell, such as a T cell. [The present invention 1007] Prior to step (i), removing said cell population from the subject. The method of the present invention 1001 further comprises: [The present invention 1008] The method of any one of claims 1002 to 1007, wherein the subject is a human subject. [The present invention 1009] The method of any of claims 1002 to 1008, wherein the subject is a humanized mouse, such as a NOD SCID gamma mouse, having umbilical cord blood stem cells. [The present invention 1010] The method of any one of claims 1001 to 1009, wherein the telomerase holoenzyme is bound to a cell-permeable peptide. [The present invention 1011] A method for increasing the proliferation potential of a cell, comprising the steps of: (i) providing a population of cells; (ii) contacting a first portion of the cell population with recombinant telomerase holoenzyme; (iii) determining the total number of cell divisions a first cell from said first portion undergoes before senescence or apoptosis is induced; (iv) determining the total number of cell divisions undergone by cells from a second, but telomerase-untreated, portion of the cell population before senescence or apoptosis is induced; and (v) determining whether a second cell from the first portion does not exhibit characteristics of cancer. The method comprising: [The present invention 1012] (iv) if the total number of cell divisions measured in step (iii) is greater than the total number of cell divisions measured in step (iv), and if the second cells from the first portion do not exhibit characteristics of cancer, introducing a third cell from the first portion into the subject. The method of the present invention 1011 further comprises: [The present invention 1013] (a) as part of step (iii), or (b) in the case of a fourth cell from said cell population, prior to step (ii), measuring telomere length and / or expression of one or more target genes that are regulated by telomere length. The method of any one of claims 1011 to 1012, further comprising: [The present invention 1014] The method of claim 1013, wherein the one or more target genes are ISG15, TEAD4, PD-1, and / or BAX. [The present invention 1015] The method of any of claims 1011 to 1014, wherein the first population of cells is PBMCs. [The present invention 1016] The first population of cells is CD3 + / CD28 + The method of any one of claims 1011 to 1014, wherein the subject is a T cell, such as a T cell. [The present invention 1017] Prior to step (i), removing said cell population from the subject. The method of the present invention 1011 further comprises: [The present invention 1018] The method of any one of claims 1012 to 1017, wherein the subject is a human subject. [The present invention 1019] The method of any of claims 1012 to 1018, wherein the subject is a humanized mouse, such as a NOD SCID γ mouse, having umbilical cord blood stem cells. [The present invention 1020] 1019. The method of any of claims 1011 to 1019, wherein the telomerase holoenzyme is bound to a cell-permeable peptide. Other objects, features, and advantages of the present disclosure will become apparent from the following detailed description, but it should be understood that the detailed description and specific examples, while illustrating certain aspects of the present disclosure, are given by way of illustration only, since various changes and modifications within the spirit and scope of the present disclosure will become apparent to those skilled in the art from this detailed description. [Brief description of the drawings]
[0015] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The present disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. [Figure 1] (Figure 1A) Telomerase activity measured by ddTRAP in stimulated T cells after stimulation with anti-CD3 / anti-CD28 Dynabeads. (Figure 1B) Telomere length measured by TeSLA (Telomere Shortest Length Assay) in stimulated T cells over a 10-day period. [Diagram 2] Correlation between telomerase activity (peak) on day 3 after stimulation and maximum cell number (a proxy for cell division rate) over a 10-day period in peripheral blood mononuclear cells (PBMCs) from 114 volunteers aged 28–113 years (unpublished data). [Diagram 3] (Figure 3A) Human TERT gene (hTERT). (Figure 3B) Recombinant hTERT carrying a biotin tag in the N-terminal domain. [Figure 4] Purification of human recombinant telomerase holoenzyme. [Diagram 5] (Figure 5A) In vitro activity of purified recombinant telomerase holoenzyme measured by ddTRAP. (Figure 5B) Identification of both TERT and other telomerase-associated proteins in the major purified complex by Western blot. (Figure 5C) Individual gels showing components of telomerase-associated proteins (dyskerin=DKC1) by Western blot. [Figure 6] (Figure 6A) PBMC composition. (Figure 6B) In vitro stimulation of T cells with anti-CD3 / anti-CD28 Dynabeads mimics physiological in vivo stimulation by antigen-presenting cells (APCs). (Figure 6C) Unstimulated PBMCs show little or no proliferative activity in vitro. (Figure 6D) PBMCs stimulated with anti-CD3 / anti-CD28 Dynabeads divide rapidly in vitro. [Figure 7](Figure 7A) Gel-based TRAP in stimulated PBMCs from a young donor over a 10-day period. (Figure 7B) ddTRAP in stimulated PBMCs from the same donor as in Figure A. The decline in telomerase activity from day 3 onwards is more easily detected compared to gel-based TRAP. (Figure 7C) Droplet digital PCR workflow. [Figure 8] (FIG. 8A) Telomere length measured by TRF shows no change in telomere length in stimulated PBMCs over 10 days. (FIG. 8B) Telomere length measured by TeSLA (Telomere Shortest Length Assay) shows progressive telomere shortening in stimulated PBMCs over 10 days. [Figure 9] Telomerase activity with or without treatment with telomerase holoenzyme. Control cells (columns 1, 3, and 5) were similarly treated with a cell-permeable peptide (not conjugated to telomerase) and specialized medium. [Figure 10] Telomerase activity from cytoplasmic and nuclear fractions of stimulated PBMCs with or without treatment with telomerase holoenzyme. Control cells were treated similarly with cell-permeable peptide (not conjugated to telomerase) and specialized medium. *p<0.05 vs. untreated [Figure 11] Average telomere length (Avg) and the shortest 20% telomere length (Short 20%) measured by TeSLA in stimulated PBMCs from young healthy adults after three consecutive deliveries of telomerase. [Figure 12] Average telomere length (Avg) and the shortest 20% telomere length (Short 20%) measured by TeSLA in stimulated PBMCs from elderly healthy individuals after three successive deliveries of telomerase. [Figure 13](FIG. 13A) Proliferation curves of stimulated PBMCs from four young adult volunteers treated three times consecutively with telomerase holoenzyme on days 3, 6, and 9. Mean population doublings in young adults (mean age 32±2 years; n=4): 15.9±3.1 PD (control) vs. 22.0±3.0 PD (+telomerase). (FIG. 13B) Proliferation curves of stimulated PBMCs from two older volunteers treated three times consecutively with telomerase holoenzyme on days 3, 6, and 9. Mean population doublings in older adults (mean age 65±3 years; n=2): 10.1±0.5 PD (control) vs. 16.0±1.6 PD (+telomerase). [Figure 14] Growth curve of aged human IMR-90 cells treated with telomerase holoenzyme every 3 days. [Figure 15] Expression levels of genes reported to be regulated by telomere length in stimulated PBMCs treated with telomerase holoenzyme. *p<0.05 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS As mentioned above, senescent cells have very limited potential for use in therapeutic applications such as adoptive immunotherapy, and therefore technologies that provide a means to efficiently protect cells from telomere loss during rapid proliferation in vitro would be highly advantageous for the successful clinical application of cells such as antigen-specific T cells.
[0017] One current strategy, known as ectopic TERT expression by retroviral cell infection (random integration sites), has been shown to significantly extend the replicative lifespan of primary human cells [18, 19]. However, a number of limitations, including the inability to transduce non-dividing cells, immunogenicity issues, and a high risk of insertional mutagenesis that can lead to oncogene activation or inactivation of tumor suppressor genes, have hindered the successful use of retroviral vectors in vivo [20, 21]. Furthermore, strategies for constitutive telomerase reactivation have raised safety concerns due to the close correlation between the majority of cancers and steady-state expression of endogenous telomerase
[22] .
[0018] Several pharmacological agents, such as sex hormones (e.g., testosterone and β-estradiol) and cycloastragenol (extracted from Chinese root Astragalus), have been reported to slightly upregulate telomerase activity in some, but not all, human cells [23–25]. However, studies performed in stimulated PBMC / T cells could not demonstrate in vitro that the upregulation of telomerase activity induced by any agent in turn promotes telomere elongation / maintenance. In addition, potential off-target effects of compounds that activate TERT at the transcriptional level (e.g., via activation of mitogenic pathways that lead to activation of the oncogene c-myc) may drive cancer [25, 26].
[0019] Thus, despite the existence of limited preliminary longitudinal studies in human volunteers reporting that oral administration of sex hormones or cycloastragenol promoted telomere maintenance in peripheral immune cells [27, 28], it remains unclear whether telomere length changes are exclusive to immune cells and why some treatments are successful and others are not (also exhibiting side effects)
[29] . Finally, other independent studies found the opposite results, reporting that mature T cells do not respond to sex hormones with changes in telomerase expression or function
[30] . Another route for transient telomerase activation involves the use of non-integrating, replication-incompetent AAV to obtain transient expression of TERT [9, 31, 32]. This approach has been extensively studied in mice but never in humans. AAV-TERT treatment (performed by tail vein injection) resulted in an extension of both lifespan and telomere length. AAV-TERT treatment also reduced / reversed various age-related diseases, including aplastic anemia and pulmonary fibrosis, and had beneficial effects on health and fitness (e.g., insulin resistance, osteoporosis, and neuromuscular coordination) [9, 31, 32]. Taken together, these studies seem to provide a preliminary proof of principle that telomerase reactivation could be an effective treatment for various ageing conditions. However, it must be pointed out that all animals used in these studies were of a pure C57BL / 6 background [9, 31, 32]. C57BL / 6 mice, the most widely used inbred strain, are highly resistant to tumors. In general, AAV can be programmed to be largely non-integrating. However, when integration of AAV vectors into the genome occurs, even as a rare event (e.g., one cell in a million), it is associated with chromosomal deletions and rearrangements
[33] , and integration occurs mainly against active genes
[34] , often leading to cancer
[35] .Considering this, AAV-TERT therapy in humans (definitely not cancer resistance) may pose a high risk to the overall health of the patient / individual, especially in the elderly population who may already have accumulated many pre-malignant changes. In addition, exogenous TERT expression is detected at high levels for at least 8 months after AAV-TERT treatment [9, 31, 32], and steady-state expression of telomerase in such a time frame may be too extensive to be considered safe in humans.
[0020] In summary, viral vector genomes have been modified by deleting certain regions of their genome to render them replication aberrant and therefore safer, but the system has several drawbacks, such as significant immunogenicity, which causes the induction of the inflammatory system and leads to degeneration of the transduced tissue; production of toxins that in turn cause cell death, and insertional mutagenesis
[36] .
[0021] Modified nucleoside-containing mRNAs are believed to be nonintegrating and have recently been used to transiently increase in vitro the levels of various proteins encoded by the transfected mRNA [37–39]. In particular, in vitro delivery of full-length TERT-encoding mRNA (up to three consecutive treatments) has been reported to transiently (24–48 h) increase telomerase activity, lengthen telomeres, and extend the replicative life span of normal human fibroblasts and myoblasts
[40] . Importantly, delivery of TERT mRNA avoided cell immortalization and delayed the expression of senescence markers
[40] . This technique appears to be safer compared to viral delivery of TERT under the control of an inducible promoter, and delivery of TERT with adenovirus or adeno-associated virus-based vectors. However, despite its potential in vitro use in stimulated T cells, delivery of hTERT mRNA may not be an ideal strategy for human interventions (especially in vivo). First, for this strategy to be successful, cells that can properly produce a functional enzyme are required: once TERT is translated, it must undergo proper post-translational modification, proper folding, and assembly with not only hTR but also several other proteins, such as DKC1 (dyskerin), NOP10, TCAB1, TPP1, RTEL1, PARN, and NAF1, that are essential for telomerase to bind telomere ends and exert its full reverse transcriptase activity
[41] . TERT is one of the most tightly regulated genes in the entire genome, due to the strict correlation between its expression and cell proliferation and, in some cases, transformation. It therefore makes sense that many cell types in the human body downregulate or silence genes that code for "accessory" proteins that are important for telomerase activity.
[0022] In addition, numerous genetic diseases are caused by defects in telomere maintenance mechanisms
[41] . These disorders are often referred to as telomeropathies and are all characterized by one common causative molecular mechanism: an adverse response to unprotected (critically shortened) telomeres. These diseases are often due to mutations involving one of several telomerase-associated proteins (DKC1, NOP10, TCAB1, TPP1, RTEL1, PARN, and NAF1), although not necessarily involving TERT. In addition, patients with hTERC mutations do not appear to generate fully active telomerase with the introduced TERT mRNA. Thus, delivery of TERT mRNA does not universally promote telomere elongation in all cell types and is potentially inefficient for treating some patients who suffer from severe telomereopathy-associated conditions, such as immune deficiencies, pulmonary fibrosis, cardiovascular disease, and bone marrow failure
[41] .
[0023] Theoretically, protein delivery is the safest approach, both in vitro and in vivo, to express the activity of gene products that are impaired or absent for various reasons. Thus, intracellular delivery of active telomerase holoenzyme (or ultimately hTERT protein) is not only a safe method but also an effective strategy, since it avoids the complex regulatory steps and most of the limitations associated with other techniques mentioned above. The present inventors are the first to explore this route and have shown that telomerase holoenzyme can be successfully introduced into cells to enhance telomerase function, thereby lengthening telomeres. These and other aspects of the present disclosure are described in detail below.
[0024] I. Telomerase Telomeres are protective structures found at the ends of linear eukaryotic chromosomes, consisting of multiple copies of TTAGGG DNA repeats. Telomeres are associated with six proteins: telomeric repeat binding factor (TRF) 1, TRF2, TIN2, Rap1, TPP1, and POT1, all of which together are referred to as the shelterin complex
[42] . Human telomeres are normally protected from cellular machinery that treats the ends of linear DNA strands as broken and in need of repair. Two major telomere-binding proteins, TRF1 and TRF2, are expressed in all human cells and associate with telomeric repeat DNA sequences throughout the cell cycle
[43] . TRF1 and TRF2 are known to associate with hRap1 and the Mre11 / Rad50 / Nbs1 DNA repair complex [44, 45]. TRF2 is also known to bind other DNA damage detection and repair factors, such as the Ku70 / 80 heterodimer [46, 47]. Heterogeneous nuclear RNPs (hnRNPs), ataxia telangiectasia mutated (ATM) kinase, and poly(ADP-ribose) polymerase (PARP) have been identified to affect telomere length [48-55]. The distal 3' end, including the telomere end, has a single-stranded overhang that can form a highly ordered structure called a t-loop
[56] . These collective components and DNA structures are involved in protecting and maintaining the DNA ends.
[0025] The human telomerase ribonucleoprotein (RNP) contains a catalytic protein component (hTERT) and a 451-base pair RNA component, human telomerase RNA (hTR), both of which are involved in telomerase activity [57, 58]. The 3' end of hTR is similar to small nucleolar RNAs (snoRNAs) of the box H / ACA family and is essential for 3' end processing, while the 5' end contains the template used for the addition of telomeric sequences to chromosome ends [59, 60]. The 5' end also contains a pseudoknot thought to be important for telomerase function, as well as a six-base pair U-rich tract required for interaction with hnRNPs C1 and C2 [61, 62].
[0026] Several other proteins have been identified to associate with the human telomerase RNP. For example, the vault protein TEP1 was the first to be identified, as well as the snoRNA-binding proteins dyskerin and hGAR1, which bind to the 3' end of hTR. The chaperone protein p23 / hsp90 has also been identified as a binding partner and is thought to be involved in the formation of active telomerase aggregates
[63] . The La autoantigen, involved in the assembly of other RNA particles and the maturation of tRNA, has been shown to interact with the telomerase RNP and to have expression levels that correlate with telomere length
[64] .
[0027] Telomeres in all normal somatic cells progressively shorten with each cell division due to the end-replication problem, which ultimately leads to cellular senescence. The end-replication problem arises because, although DNA replication is bidirectional, DNA polymerase is unidirectional and must initiate replication from a primer. Thus, with each round of DNA replication, approximately 50–200 base pairs of DNA remain unreplicated at the 3' end of each DNA strand that forms a chromosome. Left unchecked, the ends of chromosomes progressively shorten after each round of DNA replication. Replication-dependent telomerase shortening can be countered by telomerase, which adds TTAGGG repeats to the ends of linear chromosomes.
[0028] Telomerase is a reverse transcriptase enzyme because it functions to copy short RNA template sequences in hTR into DNA. Unlike retroviral reverse transcriptases, telomerase is specialized to create the short tandem repeats found at the ends of chromosomes
[65] . The protein component of telomerase, hTERT, contains a reverse transcriptase motif, and the core structure of the hTR component contains a pseudoknot, a segment of RNA that tightly interacts with the TERT protein component.
[0029] Telomerase expression is tightly regulated in normal human cells and it is found to be active in stem and germ cells. In other normal cell types, telomerase levels are typically too low to maintain telomere length over the average human lifespan [18, 19].
[0030] II. Protein Purification and Delivery The present disclosure relates in one aspect to the production and formulation of telomerase holoenzyme complexes and their delivery to cells, tissues, or subjects. In general, recombinant production of proteins is well known and therefore will not be described in detail herein.
[0031] A. Production and Purification of Telomerase Holoenzyme 1. Production Detailed information regarding the development and overexpression of recombinant human telomerase (hTERT+hTR) and the creation of the stable cell line "Super H1299" can be found in the Examples below. In addition, it should be noted that in some current and future experiments, modifications regarding the development, production, and purification of the recombinant enzyme will be adopted. The following list includes possible modifications: 1) Additional cell lines for overexpression of recombinant telomerase: FDA approved cell lines for production of human recombinant proteins (e.g., HEK293, PER.C6, CHO, P. pastoris). 2) Additional TERT tag for purification purposes: a) 3×Flag-GS10-TERT; b) HA-GS10-TERT; c) ZZ-TEV-SS-TERT; d) Biotin-TEV-cMYC-TERT. -All tags have an N-terminal localization, exactly as described for the biotin tag we developed. - In some experiments the tag is removed after purification by protease specific cleavage (TEV site). 3) Additional modifications to the TERT sequence: phosphate site substitutions to analyze the effect of phosphorylation events, or the lack thereof, on the activity, stability, and processivity of recombinant telomerase at telomeres.
[0032] Phosphorylation (the addition of a phosphate group to the side chain of an amino acid) is a common mechanism used by cells to activate or inactivate proteins as a form of regulation. In cells, proteins are usually phosphorylated at serine, tyrosine, and threonine. Some non-phosphorylated amino acids (e.g., aspartic acid) appear chemically similar to phosphorylated amino acids (e.g., phosphoserine). Thus, in a protein whose activity, stability, or processivity is enhanced by phosphorylation of that residue, when serine is replaced with aspartic acid or glutamic acid, the result is that the protein can constitutively maintain a higher level of activity, stability, or processivity. Subsequent replacement of serine, tyrosine, or threonine with alanine abolishes phosphorylation at the amino acid residue.
[0033] In some embodiments, the recombinant telomerase has / will have four modified residues: i) serine 227 substituted by aspartic acid; ii) serine 824 substituted by aspartic acid; iii) serine 921 substituted by aspartic acid, and / or iv) Threonine 249 replaced by Alanine
[0034] 2. Purification It may be desirable to purify telomerase holoenzyme according to the present disclosure. Protein purification techniques are well known to those skilled in the art. These techniques involve, at one level, crude fractionation of cellular milieu into polypeptide and non-polypeptide fractions. After separating the polypeptide from other proteins, the polypeptide of interest can be further purified using chromatographic and electrophoretic techniques to achieve partial or complete purification (or purification to homogeneity). Analytical methods that are particularly suitable for preparing pure peptides are ion exchange chromatography, exclusion chromatography; polyacrylamide gel electrophoresis; isoelectric focusing. A particularly efficient method for purifying peptides is fast protein liquid chromatography or even HPLC.
[0035] Certain aspects of the present disclosure relate to the purification, and in certain embodiments, the substantial purification, of the encoded protein or peptide. The term "purified protein" as used herein is intended to refer to a composition that can be isolated from other components, and the protein or peptide is purified to any degree relative to its naturally occurring state. Thus, a purified protein or peptide also refers to a protein or peptide that is free from the environment in which it may naturally occur.
[0036] Generally, "purified" refers to a protein composition that has been subjected to fractionation to remove various other components and that substantially retains its expressed biological activity. When the term "substantially purified" is used, this designation refers to a composition in which the protein forms a major component of the composition, for example, constituting about 50%, about 60%, about 70%, about 80%, about 90%, about 95% or more of the protein in the composition.
[0037] Various methods for quantifying the degree of purification of a protein will be known to those skilled in the art in light of the present disclosure. These include, for example, determining the specific activity of an active fraction, or assessing the amount of polypeptides in the fraction by SDS / PAGE analysis. A preferred method for assessing the purity of a fraction is to calculate the specific activity of the fraction and compare it to the specific activity of the initial extract, thereby calculating the purity, which is assessed herein by "fold purification". The actual units used to express the amount of activity will of course depend on the particular assay technique selected to track purification, and whether the expressed protein or peptide exhibits detectable activity.
[0038] A variety of techniques suitable for use in protein purification will be well known to those skilled in the art.These include, for example, precipitation with ammonium sulfate, PEG, antibody, etc., or by heat denaturation, followed by centrifugation; chromatographic steps, such as ion exchange, gel filtration, reverse phase, hydroxyapatite, and affinity chromatography; isoelectric focusing; gel electrophoresis; and combinations of such techniques and other techniques.As is generally known in the art, it may be possible to change the order in which various purification steps are carried out, or to omit certain steps, and still result in a method suitable for preparing substantially purified protein or peptide.
[0039] There is no general requirement that a protein should always be provided in the most purified state. In fact, it is contemplated that products that are substantially less purified may have utility in certain embodiments. Partial purification may be achieved by using a combination of fewer purification steps, or by utilizing different forms of the same general purification scheme. For example, it is recognized that cation exchange column chromatography performed using HPLC equipment generally results in a "-fold" higher purification than the same technique using a low pressure chromatography system. Methods that exhibit a lower degree of relative purification may be advantageous in the complete recovery of protein product or in maintaining the activity of the expressed protein.
[0040] It is known that migration of polypeptides can vary, sometimes significantly, with different conditions of SDS / PAGE
[66] , and it will therefore be appreciated that the apparent molecular weight of purified or partially purified expression products may vary under different electrophoretic conditions.
[0041] High performance liquid chromatography (HPLC) is characterized by very rapid separations with excellent peak resolution. This is achieved by the use of very fine particles and high pressure to maintain sufficient flow rates. Separation can be achieved in just a few minutes, or at most an hour. Furthermore, only small amounts of sample are required because the particles are very small and tightly packed, with the void volume being a very small fraction of the total volume. Also, the sample does not need to be very concentrated because the bands are very narrow and the sample is hardly diluted.
[0042] Gel chromatography, or molecular sieve chromatography, is a special type of partition chromatography based on molecular size. The theory behind gel chromatography is that a column made of microparticles of an inert material containing small pores separates larger molecules from smaller ones by allowing the molecules to pass through or around the pores depending on their size. Size is the only factor that determines the flow rate, unless the material forming the particles adsorbs the molecules. Thus, molecules will elute from the column in decreasing order of size, as long as their shape remains relatively constant. Gel chromatography is excellent for separating molecules of different sizes because the separation is independent of all other factors such as pH, ionic strength, temperature, etc. There is also virtually no adsorption, little zonal diffusion, and the elution volume is simply related to molecular weight.
[0043] Affinity chromatography is a chromatographic procedure that relies on the specific affinity between the substance to be isolated and a molecule to which it can specifically bind. This is a receptor-ligand type interaction. The column material is synthesized by covalently attaching one of the binding partners to an insoluble matrix. The column material is then able to specifically adsorb the substance from the solution. Elution occurs by changing the conditions to those in which binding does not occur (changing pH, ionic strength, temperature, etc.).
[0044] A particular type of affinity chromatography useful for the purification of carbohydrate-containing compounds is lectin affinity chromatography. Lectins are a class of substances that bind to a variety of polysaccharides and glycoproteins. Lectins are usually bound to agarose by cyanogen bromide. Conconavalin A bound to Sepharose was the first material of this type to be used and has been widely used in the isolation of polysaccharides and glycoproteins; other lectins include lentil lectin, wheat germ agglutinin, which has been found to be useful in the purification of N-acetylglucosaminyl residues, and snail (Helix pomatia) lectin. The lectins themselves are purified using affinity chromatography with carbohydrate ligands. Lactose has been used to purify lectins from castor beans and peanuts; maltose has been useful in extracting lectins from lentils and jack beans; N-acetyl-D-galactosamine is used to purify lectins from soybeans; N-acetylglucosaminyl binds lectins from wheat germ; D-galactosamine has been used in obtaining lectins from bivalve mollusks, and L-fucose is thought to bind lectins from lotus.
[0045] The matrix should be a material that does not itself adsorb molecules to any significant extent and has a wide range of chemical, physical, and thermal stability. The ligand should be attached in a manner that does not affect its binding properties. The ligand should also provide a relatively strong bond. And it should be possible to elute the material without destroying the sample or the ligand. One of the most common forms of affinity chromatography is immunoaffinity chromatography. The generation of antibodies that may be suitable for use with the present disclosure is discussed below.
[0046] In certain aspects, as described in more detail in the Examples, telomerase holoenzyme was purified by the following general method: Recombinant telomerase-expressing cells were lysed after culture, and the supernatant was collected. Gradient ultracentrifugation was performed and fractionated into 11 fractions (1 mL each). The last 5 fractions contained almost all the telomerase activity. These fractions were pooled together and incubated with monomeric avidin beads, after which the beads were subjected to microbio-spin chromatography. The flow-through was collected and the beads were washed. The enriched telomerase was then eluted in three fractions, which were pooled together and subjected to bead-based chromatography. The flow-through was collected, the beads were washed, and then the telomerase was eluted. The eluted fractions (E2, E3, and E4) were pooled together and used for subsequent assays and experiments.
[0047] B. Cell delivery The present disclosure contemplates the use of cell penetrating peptides (CPPs, also referred to as cell delivery peptides or cell transduction domains) linked to telomerase. The intrinsic properties of CPPs indicate that they may be potential components of future drugs and disease diagnostics [67, 68]. CPPs are relatively simple to synthesize and characterize, and can deliver attached bioactive proteins into cells in a non-toxic manner, primarily via endocytosis. Importantly, CPPs are passive and non-selective (universally applicable to all cell types), but can also be functionalized or chemically modified to create effective delivery vectors that target specific cells or tissues (or specific cell types in a heterogeneous cell population such as PBMCs). Thus, CPPs provide a useful platform for the potential development of medical treatments with complex proteins such as telomerase, long thought to be untherapeutic.
[0048] We utilized CPPs to transiently deliver purified telomerase holoenzyme to normal young and old antigen-stimulated human peripheral blood mononuclear cells (PBMCs) and lung fibroblasts (IMR-90). In particular, we combined the efficacy of CPPs with a recently developed method that reported an active uptake mechanism in which NaCl-mediated hyperosmolarity induces macropinocytotic uptake and intracellular release of exogenous proteins
[69] (telomerase holoenzyme is eluted in a specific NaCl / HNa2PO4 buffer characterized by hyperosmolarity).
[0049] CPPs have been described in the art and are generally characterized as short, amphipathic or cationic peptides and peptide derivatives that often contain multiple lysine and arginine residues
[70] . Further examples are shown in Table 1 below.
[0050] Table 1: CDD / CTD peptides TIFF2024156858000001.tif169146
[0051] IV. Methods for Treating Cells A. Cells and Culture As mentioned above, the present disclosure provides for increasing telomere length in cells.Generally, the cells to be treated can be any cells, but in particular, the present inventors intend to treat engineered T cells for use in adoptive immunotherapy.However, other specific cell types of interest include hematopoietic stem cells from bone marrow, lung epithelial cells, liver cells, and unfertilized eggs (before in vitro fertilization).
[0052] The method involves contacting a target cell or cell population with purified telomerase holoenzyme, as described above. In general, "contacting" is understood to mean bringing the holoenzyme into sufficient proximity with one or more cells so that the cellular uptake machinery is activated and the holoenzyme is introduced into the cells. Thus, the cells can be contacted with a unit dose of the holoenzyme preparation or perfused with a culture medium containing a specific concentration of the holoenzyme, optionally in this case the holoenzyme in the medium is replenished to maintain a specific concentration over time. The concentration of purified recombinant telomerase holoenzyme varies slightly from batch to batch, which mainly depends on the number of cells used for protein purification (in our case, 1-5 billion cells). After each purification, we measured the total activity of 1 μl of purified telomerase by ddTRAP, a highly quantitative assay for determining the number of telomerase molecules per cell
[71] . The activity is expressed in arbitrary units, with one unit corresponding to one TS primer successfully extended by telomerase during the ddTRAP protocol and subsequently amplified. In the experiments described herein, we consistently observed 5×10 9 of telomerase units were delivered.
[0053] The cells can be obtained from any source, such as a human or animal, including cells from an animal that is to be subsequently re-injected with treated cells (i.e., autologous cell therapy). The cells can also be cell lines, or cells that have been previously engineered with one or more heterologous constructs.
[0054] B. Formulations Where clinical applications are contemplated, the cell preparations are prepared in a form appropriate for the intended application. Generally, this entails preparing a composition that is essentially free of pyrogens and other impurities that may be harmful to cells, humans, or animals.
[0055] Generally, it will be desirable to utilize appropriate salts and buffers to stabilize the enzyme and allow uptake by the target cells. The aqueous compositions of the present disclosure comprise an effective amount of the protein dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. The phrase "pharmaceutically or pharmacologically acceptable" refers to molecular entities and compositions that do not produce adverse, allergic, or other undesirable reactions when administered to animals or humans. As used herein, "pharmaceutically acceptable carriers" include solvents, buffers, solutions, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and absorption delaying agents, etc., that are acceptable for use in formulating pharmaceuticals, such as pharmaceuticals suitable for administration to humans. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredients of the present disclosure, its use in the therapeutic composition is contemplated. Supplementary active ingredients can also be incorporated into the composition, so long as they do not inactivate the enzyme or cells.
[0056] The active composition of the present disclosure may include classical pharmaceutical preparations. For example, a solution of the active compound as a free base or a pharmacologically acceptable salt can be prepared in water, suitably mixed with a surfactant such as hydroxypropylcellulose. Suitable solvents or dispersion media may contain, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils. Proper fluidity can be maintained, for example, by the use of a coating agent such as lecithin, by maintaining the required particle size in the case of dispersion, and by the use of surfactants. Prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. It may be desirable to include an isotonic agent, for example, sugar or sodium chloride.
[0057] Sterile solution can be prepared by incorporating the appropriate amount of active compound into a solvent with any other ingredients (e.g., as listed above) as desired, and then sterilizing by filtration.Generally, dispersion is prepared by incorporating various sterilized active ingredients into a sterile medium that contains, for example, a basic dispersion medium as listed above and other desired ingredients.In the case of sterile powder for preparing sterile injectable solution, the preferred preparation method includes vacuum drying and freeze-drying techniques, which produce a powder of active ingredient and any additional desired ingredients from the solution that has been previously sterile-filtered.
[0058] When formulated, solutions are preferably used in a manner compatible with the dosage formulation, and in an amount that is therapeutically effective (see, e.g., Remington's Pharmaceutical Sciences, 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage may occur depending on the particular target cells. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety, and purity standards as required by FDA Office of Biologics standards. EXAMPLES
[0059] IV. Working Examples The following examples are included to further illustrate various aspects of the present disclosure.It should be recognized by those skilled in the art that the techniques disclosed in the following examples represent the techniques and / or compositions that the inventors have discovered to work well in implementing the present disclosure, and therefore can be considered to constitute the preferred mode for its implementation.However, those skilled in the art should recognize that in light of the present disclosure, many changes can be made in the specific embodiments disclosed and still obtain the same or similar results without departing from the spirit and scope of the present disclosure.
[0060] Example 1 - Methods Development and overexpression of recombinant human telomerase (hTERT+hTR) and generation of the stable cell line Super H1299 The engineered recombinant hTERT contains an in vivo biotinylation sequence, a Tev protease cleavage site, a cMyc tag, and an additional 99 amino acid residues before the hTERT sequence, preceding the N-terminus of hTERT. TIFF2024156858000002.tif11149. The conserved biotinylation sequence is biotinylated at the conserved MKM site in mammalian cells. The modified hTERT plasmid and the exogenous hTR plasmid were packaged into retroviral and lentiviral vectors, respectively, and used to transfect to generate a stable cell line that we call Super H1299. After hygromycin selection, the cells were expanded and harvested on a weekly basis and used for various experiments.
[0061] Biotin-tagged hTERT carried in the pBabe-hygro retroviral vector was transfected into the transient packaging line PhoenixE. The virus-containing supernatant was then used to infect the stable amphotropic packaging line PA317. PA317 cells were then selected with hygromycin to produce stable virus that was used to infect the expression cell line H1299. Infected H1299 cells were selected with hygromycin.
[0062] For hTR, the pSSI 7661 lentiviral vector was used with two helper plasmids, psPAX2 and pMD2G, to transfect 293 packaging cells. The viral supernatant was used to infect H1299 cells expressing biotinylation sequence-tagged hTERT. The infected H1299 cells were further selected with blasticidin and hygromycin.
[0063] Purification of recombinant telomerase from Super H1299 (3 steps) 200 million frozen cell pellets of super H1299 cells were lysed in 1.5% CHAPS lysis buffer (10% glycerol, 1 mM EGTA pH 8.0, 0.1 mM MgCl2, 10 mM Tris-HCL, 0.01 mM PMSF, 1 unit RiboLock RNAse inhibitor, and 1 unit PI cocktail) for 30 min with rotation at 4 °C. The cells were then centrifuged at 17,500 × g for 1 h at 4 °C. The supernatant was collected and placed in a clean tube. A 10 ml continuous glycerol gradient (10-30%) was made with a gradient maker (glycerol, 20 mM HEPES pH 7.5, 300 mM KCl, 0.1 mM MgCl2, 0.1% Triton X-100, and 1 mM EGTA). The cell lysate sample was loaded onto the top of the gradient, followed by ultracentrifugation at 126,000 × g for 19 hours at 4 °C (SW41 Beckman rotor). The gradient was fractionated into 11 fractions (1 mL each). The bottom 5 fractions contained nearly all the telomerase activity. These 5 fractions (7–11) were pooled together and incubated with monomeric avidin beads (Peirce) for 2 hours at 4 °C. After incubation, the beads were placed into a microbio-spin chromatography column (BioRad). The flow-through solution was collected and the beads were washed twice with 5 ml of buffer containing 150 mM sodium phosphate, pH 7.0 and 100 mM NaCl. The concentrated telomerase was then eluted with 400 mM NaCl, 150 mM sodium phosphate buffer pH 7.0, and 4 mM D-biotin (Pierce). Telomerase activity was eluted into three fractions of 1 ml each. These elution fractions were pooled together and incubated with the final column, SP (sulfopropyl) Sepharose Fast Flow (SPFF). The SPFF resin was equilibrated in 50 mM sodium phosphate (pH 7.0) and 50 mM NaCl prior to incubation with telomerase. Telomerase was incubated with the SPFF beads for 2 hours at 4°C. After incubation, the beads were loaded onto a microbio-spin column.The flow-through was collected and the SPFF beads were washed twice with 5 ml of buffer made up of 20 mM sodium phosphate pH 7.0 and 50 mM NaCl. Telomerase was then eluted with a NaCl salt gradient (6 steps from 200 mM to 500 mM). This was done in 6 separate elution fractions (500 μl). The eluate from 500 mM contained the majority of the telomerase activity. These elution fractions (E2, E3, and E4) were pooled together and used for subsequent assays and experiments.
[0064] Isolation, stimulation, and treatment of PBMCs with telomerase holoenzyme Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood of healthy volunteers by centrifugation over Ficoll-Paque Plus (GE Healthcare) and then stored frozen at -140°C until analysis. Cells were thawed 24 hours before mitogenic stimulation and cultured in RPMI+GlutaMAX-I supplemented with 10% fetal bovine serum, 10 ng / ml IL-2, 1% penicillin, streptomycin, and amphotericin B. After 24 hours, the cell suspension was transferred to a new flask to remove monocytes (adherent to the flask plastic).
[0065] PBMCs were stimulated by adding a 1:1 ratio of Dynabeads Human T-Activator CD3 / CD28 (Life Technologies). 72 h after stimulation, Dynabeads were removed using a magnet and cells were cultured for up to 35 days after stimulation. Cells were restimulated every 8–10 days. The percentage of viable cells was determined daily by trypan blue exclusion using a TC20 automated cell counter (Bio-Rad). Cell density was adjusted daily to a concentration of 1.5 × 10 6 If the number of cells exceeded 1.0 × 10 cells / ml, resuspend the cells in fresh complete RPMI medium at 1.0 × 10 6 The cells were diluted to a density of 100 / ml.
[0066] Telomerase holoenzyme was delivered three consecutive times on days 3, 6, and 9 after stimulation. Before delivery, cells were centrifuged at 500 g for 15 min and resuspended in serum-free RPMI+GlutaMAX-I supplemented with 10 ng / ml IL-2 and 200 U / ml recombinant ribonuclease inhibitor. Telomerase holoenzyme in 500 mM NaCl and 50 mM sodium phosphate pH 7.0 was mixed with a cell-penetrating peptide (Xfect kit, Protein Transfection Protocol, Takara) and added to cells resuspended in serum-free medium. After 1 h of incubation at 37°C, cells were centrifuged at 500 g for 15 min, resuspended in complete medium (RPMI+GlutaMAX-I supplemented with 10% fetal bovine serum, 10 ng / ml IL-2, 1% penicillin, streptomycin, and amphotericin B) and cultured at 37°C, 5% CO2.
[0067] Example 2 - Results Holoenzyme production We have successfully engineered a biotin-tagged recombinant hTERT and overexpressed it together with hTR (the functional RNA component of telomerase) in human cells. We have also developed a three-step purification procedure strategy to obtain the recombinant enzyme.
[0068] A multi-step purification procedure allowed us to obtain highly enriched, catalytically active enzyme. Importantly, the utilized biotin tag (developed by us) allowed us to pull down the entire reconstituted holoenzyme complex, including not only telomerase but also other essential telomerase-associated proteins such as dyskerin (DKC1) and ribonucleoproteins NOP10 and NHP2.
[0069] PBMC PBMCs are a heterogeneous cell population consisting primarily of T cells, the major component of the human immune response. When unstimulated, T cells are resting or quiescent and exhibit little or no proliferative activity. In contrast, upon antigen-specific activation, T cells divide rapidly and exhibit dramatic changes in gene expression
[72] .
[0070] Activated T cells initiate immune responses, such as discriminating between healthy and abnormal (e.g., infected or cancerous) cells in the body, and are increasingly being used as a key tool in adoptive immunotherapy to treat various forms of cancer and infectious diseases such as AIDS [16, 17]. We stimulated PBMCs in exactly the same way to activate and expand engineered CAR-T cells
[73] , except that we did not utilize a WAVE bioreactor for cell culture and did not pre-transfect PBMCs with the 4-1BB receptor.
[0071] ddTRAP To measure telomerase activity, we utilized the droplet digital PCR assay (ddTRAP) previously developed in our laboratory
[71] . ddTRAP is a digital, high-throughput, and sensitive assay that provides absolute quantification of telomerase activity at the single-cell level. Importantly, this improved technique can discriminate between samples with only a 10% difference in telomerase activity, in contrast to gel-based TRAP (still predominantly used in the field, but only semi-quantitative).
[0072] Telomere Minimum Length Assay (TeSLA) Telomere length was measured using a new, highly sensitive and accurate assay (TeSLA, Telomere Minimum Length Assay ( Te lomere S hortest L ength ATeSLA was used to measure telomere length in human immune cells by using a telomere length assay
[74] . TeSLA allows for the simultaneous measurement of both the average telomere length and the length of the shortest 20% of telomeres. Importantly, in contrast to both TRF and Q-FISH (currently the gold standard in the field), TeSLA is able to detect small variations in telomere length, such as the physiological telomere attrition that occurs in human immune cells over a period of one year
[74] . Using TeSLA, we were able to demonstrate progressive telomere shortening over a 10-day period in stimulated PBMCs expanded in vitro.
[0073] Using ddTRAP, we successfully delivered purified telomerase holoenzyme to the cytoplasmic compartment of different normal human cell types, including quiescent and stimulated PBMCs, and demonstrated that the delivered complexes maintained robust activity.
[0074] Next, we demonstrated that the delivered telomerase was then transported to the nucleus. To this end, cells were fractionated into cytoplasmic and nuclear compartments and ddTRAP was performed in the two separate fractions. Telomerase activity from both the cytoplasmic and nuclear fractions increased significantly after delivery, indicating that the purified telomerase complex can cross the nuclear membrane (potentially through the nuclear pores) and reach the nucleus.
[0075] To determine whether the delivered telomerase also maintained its ability to add TTAGGG repeats to telomere ends and whether the biotin tag utilized affected the ability of the enzyme to bind telomeres intracellularly, telomere length was measured in stimulated PBMCs treated with telomerase.
[0076] We delivered telomerase holoenzyme three times (days 3, 6, and 9) to stimulated PBMCs from four young adults (mean age 32 ± 2 years) and two older volunteers (mean age 65 ± 3 years). Telomerase delivery significantly reduced the rate of telomere shortening during rapid cell proliferation (see Figure 11, which depicts TeSLA profiles of four individuals). Importantly, this treatment preferentially extended the length of the shortest telomeres, which are believed to best correlate with cell viability and chromosomal stability, as well as various age-related diseases and phenotypes of aging
[75] .
[0077] We then demonstrated that the treatment also extended the replicative life span of T cells. Cells were counted electronically daily, including trypan blue exclusion, until they showed no signs of proliferation for at least three consecutive days. We also treated aged human lung fibroblasts (every three days) and demonstrated that delivery of telomerase holoenzyme is generally applicable to normal telomerase-negative cells and adherent cell cultures.
[0078] We previously identified a group of genes whose expression is directly regulated by telomere length (telomere position effects over long distances, TPE-OLD) [76, 77]. In these studies, the presence of long telomeres resulted in telomeric “chromosomal loops” approaching genes up to 10 Mb away from the telomere end. In cells with short telomeres, these intervening telomeric loops were lost and the same loci were separated
[77] . Telomere loop formation promotes epigenetic regulation of gene expression (generally silencing gene expression). Thus, TPE-OLD is a mechanism by which progressive telomere shortening directly causes changes in gene expression that, in turn, may contribute to the initiation / progression of aging and disease long before telomeres are short enough to trigger significant DNA damage responses and senescence
[77] .
[0079] We measured the expression levels of some of these genes by ddPCR and found that telomere elongation induced by delivery of telomerase holoenzyme also correlated with changes in gene expression. Those genes involved in inflammatory pathways and apoptosis signaling are regulated by telomere loop formation, and changes in their expression levels may precede cellular replicative senescence. This suggests that this is also sufficient to change gene expression to a more "young" profile by preventing telomere shortening, a hallmark of aging. These genes and their expression are potential biomarkers of the effectiveness of telomerase delivery.
[0080] We analyzed the genome-wide expression profiles of stimulated PBMCs treated with telomerase holoenzyme in comparison to untreated controls. By comparing this new dataset with a dataset from a study of healthy versus frail centenarians, we found that telomerase holoenzyme-treated cells differentially modulated the expression of genes strongly associated with healthy aging and longevity (data not shown).
[0081] All compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of this disclosure.Although the compositions and methods of this disclosure have been described in terms of preferred embodiments, it will be apparent to those skilled in the art that modifications may be made to the compositions and methods described herein, and in the steps or sequence of steps of such methods, without departing from the concept, spirit and scope of this disclosure.More specifically, it will be apparent that certain agents that are both chemically and physiologically related may be substituted for the agents described herein, and still achieve the same or similar results.All such similar substitutes and modifications that are apparent to those skilled in the art are deemed to be within the spirit, scope and concept of this disclosure, as defined by the appended claims.
[0082] VII. References The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference. TIFF2024156858000003.tif190150TIFF2024156858000004.tif231150TIFF2024156858000005.tif223150TIFF20241568580 00006.tif217150TIFF2024156858000007.tif217150TIFF2024156858000008.tif231150TIFF2024156858000009.tif169150
[0083] Sequence information SEQUENCE LISTING <110> The Board of Regents of the University of Texas System <120> TELOMERASE HOLOENZYME COMPLEX AND METHODS OF USE THEREOF <150> US 62 / 727,743 <151> 2018-09-06 <160> 45 <170> PatentIn version 3.5 <210> 1 <211> twenty three <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 1 Gly Ala Leu Phe Leu Gly Trp Leu Gly Ala Ala Gly Ser Thr Met Gly 1 5 10 15 Ala Lys Lys Lys Arg Lys Val 20 <210> 2 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 2 Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 3 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 3 Arg Arg Met Lys Trp Lys Lys 1 5 <210> 4 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 4 Arg Arg Trp Arg Arg Trp Trp Arg Arg Trp Trp Arg Arg Trp Arg Arg 1 5 10 15 <210> 5 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 5 Arg Gly Gly Arg Leu Ser Tyr Ser Arg Arg Arg Phe Ser Thr Ser Thr 1 5 10 15 Gly Arg <210> 6 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 6 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5 10 <210> 7 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 7 Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5 <210> 8 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 8 Tyr Ala Arg Ala Ala Ala Arg Gln Ala Arg Ala 1 5 10 <210> 9 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 9 Arg Arg Arg Arg Arg Arg Arg 1 5 <210> 10 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 10 Lys Lys Lys Lys Lys Lys 1 5 <210> 11 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <220> <221> misc_feature <222> (25)..(25) <223> It can be any naturally occurring amino acid. <400> 11 Gly Trp Thr Leu Asn Serves Ala Gly Tyr Leu Gly Lys Ile Asn Leu 1 5 10 15 Lys The Lion The Lion The Lion The Lys Xaa The Lion Island 20 25 <210> 12 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 12 Leu Leu Ile Leu Leu Arg Arg Arg Ile Arg Lys Gln Ala Asn Ala His 1 5 10 15 Ser Lys <210> 13 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 13 Ser Arg Arg His His Cys Arg Ser Lys Ala Lys Arg Ser Arg His His 1 5 10 15 <210> 14 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 14 Asn Arg Ala Arg Arg Asn Arg Arg Arg Val Arg 1 5 10 <210> 15 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 15 Arg Gln Leu Arg Ile Ala Gly Arg Arg Leu Arg Gly Arg Ser Arg 1 5 10 15 <210> 16 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 16 Lys Leu Ile Lys Gly Arg Thr Pro Ile Lys Phe Gly Lys 1 5 10 <210> 17 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 17 Arg Arg Ile Pro Asn Arg Arg Pro Arg Arg 1 5 10 <210> 18 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 18 Lys Leu Ala Leu Lys Leu Ala Leu Lys Ala Leu Lys Ala Ala Ala Leu Lys 1 5 10 15 Leu Wing <210> 19 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 19 Lys Leu Ala Lys Leu Ala Lys Lys Leu Ala Lys Leu Ala Lys 1 5 10 <210> 20 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 20 Gly Ala Leu Phe Leu Gly Phe Leu Gly Ala Ala Gly Ser Thr Asn Gly 1 5 10 15 Ala Trp Ser Gln Pro Lys Lys Lys Arg Lys Val 20 25 <210> 21 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 21 Lys Glu Thr Trp Trp Glu Thr Trp Trp Thr Glu Trp Ser Gln Pro Lys 1 5 10 15 Lys Lys Arg Lys Val 20 <210> 22 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 22 Leu Lys Lys Leu Leu Lys Lys Leu Leu Lys Lys Leu Leu Lys Lys Leu 1 5 10 15 Leu Lys Lys Leu 20 <210> 23 <211> 34 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 23 Gln Ala Ala Thr Ala Thr Arg Gly Arg Ser Ala Ala Ser Arg Pro Thr 1 5 10 15 Glu Arg Pro Arg Ala Pro Ala Arg Ser Ala Ser Arg Pro Arg Arg Pro 20 25 30 Val Glu <210> 24 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 24 Put Gly Leu Gly Leu His Leu Leu Val Leu Ala Ala Ala Leu Gln Gly 1 5 10 15 Ala Lys Dear Lys Arg Lys Val 20 <210> 25 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 25 Wing Wing Val Wing Slow Slow Pro Wing Val Slow Slow Wing Slow Slow Wing Pro 1 5 10 15 Ala Ala Ala Asn Tyr Lys Lys Pro Lys Leu 20 25 <210> 26 <211> 28 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 26 Met Ala Donkey Gly Tyr Trp Leu Leu Ala Leu Phe Val Thr Met Trp 1 5 10 15 Thr Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro 20 25 <210> 27 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 27 Leu Gly Thr Tyr Thr Gln Asp Phe Asn Lys Phe His Thr Phe Pro Gln 1 5 10 15 Thr Ala Ile Gly Val Gly Ala Pro 20 <210> 28 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <220> <221> misc_feature <222> (24)..(24) <223> Xaa can be any naturally occurring amino acid <400> 28 Asp Pro Lys Gly Asp Pro Lys Gly Val Thr Val Thr Val Thr Val Thr 1 5 10 15 Val Thr Gly Lys Gly Asp Pro Xaa Pro Asp 20 25 <210> 29 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 29 Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro 1 5 10 <210> 30 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 30 Val Arg Leu Pro Pro Pro Val Arg Leu Pro Pro Pro Val Arg Leu Pro 1 5 10 15 For For <210> 31 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 31 Pro Arg Pro Leu Pro Pro Pro Arg Pro Gly 1 5 10 <210> 32 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 32 Ser Val Arg Arg Arg Pro Arg Pro Pro Tyr Leu Pro Arg Pro Arg Pro 1 5 10 15 Pro Pro Phe Phe Pro Pro Arg Leu Pro Pro Arg Ile Pro Pro 20 25 30 <210> 33 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 33 Thr Arg Ser Ser Arg Ala Gly Leu Gln Phe Pro Val Gly Arg Val His 1 5 10 15 Arg Leu Leu Arg Lys 20 <210> 34 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 34 Gly Ile Gly Lys Phe Leu His Ser Ala Lys Lys Phe Gly Lys Ala Phe 1 5 10 15 Val Gly Glu Ile Met Asn Ser 20 <210> 35 <211> 37 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 35 Lys Trp Lys Leu Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile Arg 1 5 10 15 Asp Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln Ala 20 25 30 Thr Gln Ile Ala Lys 35 <210> 36 <211> 28 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 36 Ala Leu Trp Met Thr Leu Leu Lys Lys Val Leu Lys Ala Ala Ala Lys 1 5 10 15 Ala Ala Leu Asn Ala Val Leu Val Gly Ala Asn Ala 20 25 <210> 37 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 37 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu 1 5 10 15 Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln 20 25 <210> 38 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 38 Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu 1 5 10 <210> 39 <211> 33 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 39 Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Pro Lys 1 5 10 15 Thr Leu Leu Ser Ala Val Gly Ser Ala Leu Gly Gly Ser Gly Gly Gln 20 25 30 Glu <210> 40 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 40 Leu Ala Lys Trp Ala Leu Lys Gln Gly Phe Ala Lys Leu Lys Ser 1 5 10 15 <210> 41 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <220> <221> misc_feature <222> (23)..(23) <223> Xaa can be any naturally occurring amino acid <400> 41 Ser Met Ala Gln Asp Ile Ile Ser Thr Ile Gly Asp Leu Val Lys Trp 1 5 10 15 Ile Ile Gln Thr Val Asn Xaa Phe Thr Lys Lys 20 25 <210> 42 <211> 41 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 42 Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu 1 5 10 15 Phe Lys Arg Ile Val Gln Arg Ile Lys Gln Arg Ile Lys Asp Phe Leu 20 25 30 Ala Asn Leu Val Pro Arg Thr Glu Ser 35 40 <210> 43 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 43 Pro Ala Trp Arg Lys Ala Phe Arg Trp Ala Trp Arg Met Leu Lys Lys 1 5 10 15 Ala Ala <210> 44 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 44 Lys Leu Lys Leu Lys Leu Lys Leu Lys Leu Lys Leu Lys Leu Lys Leu 1 5 10 15 Lys Leu <210> 45 <211> 99 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 45 Met Ala Gly Lys Ala Gly Glu Gly Glu Ile Pro Ala Pro Leu Ala Gly 1 5 10 15 Thr Val Ser Lys Ile Leu Val Lys Glu Gly Asp Thr Val Lys Ala Gly 20 25 30 Gln Thr Val Leu Val Leu Glu Ala Met Lys Met Glu Thr Glu Ile Asn 35 40 45 Ala Pro Thr Asp Gly Lys Val Glu Lys Val Leu Val Lys Glu Arg Asp 50 55 60 Ala Val Gln Gly Gly Gln Gly Leu Ile Lys Ile Gly Val Glu Asn Leu 65 70 75 80 Tyr Phe Gln Ser Thr Met Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu 85 90 95 Glu Phe Thr
Claims
1. 1. A method for increasing telomere length and / or increasing the proliferative potential of a cell, comprising: (i) providing a population of cells; (ii) contacting at least a first portion of the cell population with purified recombinant telomerase holoenzyme; and (iii) measuring expression of one or more target genes that are regulated by telomere length in cells from said first portion. The method comprising:
2. (iv) introducing a second cell from the first portion into the subject if one or more of the target genes exhibit an expression profile indicative of telomerase activity compared to an untreated cell, such as an untreated cell, from a second portion of the cell population. The method of claim 1, further comprising:
3. prior to step (ii), measuring expression of one or more target genes that are regulated by telomere length in a third cell of said cell population.
3. The method of claim 1 or 2, further comprising:
4. The method of any one of claims 1 to 3, wherein the one or more target genes are ISG15, TEAD4, PD-1, and / or BAX.
5. The method of any one of claims 1 to 4, wherein the cell population is PBMC.
6. The cell population is CD3 + / CD28 + The method of any one of claims 1 to 4, wherein the cell is a T cell, such as a T cell.
7. Prior to step (i), removing said cell population from the subject. The method of claim 1, further comprising:
8. The method of any one of claims 2 to 7, wherein the subject is a human subject.
9. The method according to any one of claims 2 to 8, wherein the subject is a humanized mouse, such as a NOD SCID gamma mouse, having umbilical cord blood stem cells.
10. The method of any one of claims 1 to 9, wherein the telomerase holoenzyme is linked to a cell-permeable peptide.
11. A method for increasing the proliferation potential of a cell, comprising the steps of: (i) providing a population of cells; (ii) contacting a first portion of the cell population with recombinant telomerase holoenzyme; (iii) determining the total number of cell divisions a first cell from said first portion undergoes before senescence or apoptosis is induced; (iv) determining the total number of cell divisions undergone by cells from a second, but non-telomerase-treated, portion of the cell population before senescence or apoptosis is induced; and (v) determining whether a second cell from the first portion does not exhibit characteristics of cancer. The method comprising:
12. (iv) if the total number of cell divisions measured in step (iii) is greater than the total number of cell divisions measured in step (iv), and if the second cells from the first portion do not exhibit characteristics of cancer, introducing a third cell from the first portion into the subject.
12. The method of claim 11, further comprising:
13. (a) as part of step (iii), or (b) in the case of a fourth cell from said cell population, prior to step (ii), measuring telomere length and / or expression of one or more target genes that are regulated by telomere length.
13. The method of claim 11 or 12, further comprising:
14. 14. The method of claim 13, wherein the one or more target genes are ISG15, TEAD4, PD-1, and / or BAX.
15. The method of any one of claims 11 to 14, wherein the first population of cells is PBMCs.
16. The first population of cells is CD3 + / CD28 + The method of any one of claims 11 to 14, wherein the cell is a T cell, such as a T cell.
17. Prior to step (i), removing said cell population from the subject.
12. The method of claim 11, further comprising:
18. The method according to any one of claims 12 to 17, wherein the subject is a human subject.
19. The method according to any one of claims 12 to 18, wherein the subject is a humanized mouse, such as a NOD SCID gamma mouse, having umbilical cord blood stem cells.
20. The method of any one of claims 11 to 19, wherein the telomerase holoenzyme is linked to a cell-permeable peptide.
